<DOC>
	<DOCNO>NCT00493402</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , patient report outcome ( PRO ) different regimens transarterial chemoembolization ( TACE ) patient hepatocellular carcinoma ( HCC ) .</brief_summary>
	<brief_title>Different Regimens Transarterial Chemoembolization Hepatocellular Carcinoma</brief_title>
	<detailed_description>Transarterial chemoembolization ( TACE ) recommend first line non-curative therapy non-surgical patient large/multifocal HCC vascular invasion extrahepatic spread . There standardize protocol choice chemotherapeutic agent , dosage , dilution , rate injection , time interval treatment . Similarly , agreement choice embolizing agent , degree embolization , whether chemotherapeutic agent give together , embolizing agent . Comparison ( ) : In patient HCC underwent TACE therapy , stratify whether vascular invasion tumor size , compare efficacy , safety , patient report outcome ( PRO ) different regimen TACE . Regimen 1 : lipiodol combine chemotherapy embolization Regimen 2 : lipiodol combine chemotherapy without embolization Regimen 3 : lipiodol single agent chemotherapy embolization</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>Adult patient minimal height 150cm minimal weight 50 KG Histological confirm HCC previous treatment With unresectable tumor With solitary multiple intrahepatic tumor , diameter large one must large 7cm . No significant baseline liver dysfunction . Cirrhotic status ChildPugh class A No significant renal impairment ( creatinine clearance &lt; 30 mL/minute ) The following laboratory parameter : Platelet count ≥ 60,000/µL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 1.5 mg/dL ASL AST ≤ 5 x upper limit normal Serum albumin ≥ 35 g/L Serum creatinine ≤ 1.5 x upper limit normal INR ≤ 1.5 Pt/PTT within normal limit Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Ability understand protocol agree sign write informed consent document Avascular tumor Main portal vein obstruction without cavernous transformation Evidence hepatic decompensation include esophageal gastric variceal bleed hepatic encephalopathy Obstructive jaundice Severe underlie cardiac renal disease Known suspect allergy investigational agent agent give association trial Pregnant breastfeeding patient . History organ allograft Active clinically serious infection Any condition unstable could jeopardize safety patient his/her compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>administration &amp; dosage</keyword>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Chemoembolization , Therapeutic</keyword>
	<keyword>Humans</keyword>
	<keyword>Liver Neoplasms</keyword>
	<keyword>therapy</keyword>
</DOC>